Company intelligence / Profile preview

Inovio Payments

Plymouth Meeting, Pennsylvania, United Statesinoviopay.com ↗

Ownership: Private
Development stage: Commercial

Overview

Inovio has advanced multiple programs into mid-to-late stage clinical trials. VGX‑3100 has shown efficacy in treating HPV-related precancerous lesions. Other candidates are in development for cancers and infectious diseases. The company’s proprietary CELLECTRA® device enhances delivery of its DNA medicines.

Therapeutic areas: OncologyInfectious DiseasesWomen's Health
Modalities: DNA vaccineDNA immunotherapyVaccine
Industry: Biotech

Partnerships

Government agencies and collaborations on infectious disease vaccines and therapies

Beyond the preview

Go deeper on Inovio Payments.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inovio Payments.

Explore the full profile